Related Experiment Videos
Massive doses of procainamide for ventricular tachyarrhythmias due to myocardial infarction
Insights
Massive intravenous procainamide doses prevented ventricular arrhythmias in post-myocardial infarction patients. Unexpectedly low serum concentrations and no side effects were observed, suggesting unique metabolic factors in slow acetylators.
Area of Science:
- Cardiology
- Clinical Pharmacology
Background:
- Malignant ventricular arrhythmias pose a significant risk following acute myocardial infarction.
- Effective management of these arrhythmias is crucial for patient survival.
Observation:
- Three patients developed ventricular arrhythmias during reinfarction days after initial hospitalization.
- Massive intravenous procainamide (up to 7.5 g/day) was required to control these arrhythmias.
Findings:
- Procainamide serum concentrations were 2-4 times above recommended levels, yet no adverse effects were noted.
- Expected serum concentrations were not reached despite high intravenous doses.
- Potential factors include renal function, intestinal losses, tissue storage, and unknown metabolic pathways in slow acetylator patients.
Implications:
- This case series highlights potential variability in procainamide pharmacokinetics.
- Further research into procainamide metabolism in slow acetylators is warranted.
- Clinical practice may need to consider individualized dosing strategies for procainamide in specific patient populations.
Abstract:
Three patients are described in whom malignant ventricular arrhythmias appeared in connection with a reinfarction some days after hospitalization for an acute myocardial infarction and in whom massive doses of procainamide, up to 7.5 g/day i.v., were necessary to prevent these arrhythmias. The serum concentration of procainamide was 2--4 times higher than the recommended upper level, but no side-effects were observed. With the dose given, one would have expected still higher serum concentrations. Several reasons for this finding are discussed, including the effects of renal function, intestinal leakage, storage of the drug in tissues and hitherto unknown metabolic pathways of procainamide in patients, who are slow acetylators.